Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

NCT04860700 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT04860700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04860700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2021
Completion date
October 17, 2023
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant adrenal gland pheochromocytoma, malignant paraganglioma, paraganglioma, extra-adrenal, paraganglioma, malignant, pheochromocytoma, metastatic